Tetratherix (ASX:TTX) said that all patient follow-ups from the first patient group under its clinical study for its TetraDerm product for the potential prevention of scar formation in surgical incisions were completed, showing that the scarring was restricted to 13% at three months and further reduced to 8% after 12 months, according to a Tuesday Australian bourse filing.

The one-year follow-up results indicated that when the product is laid between layers of skin tissue before final wound closure, there was negligible scar formation in these patients, with an average Vancouver Scar Scale score of 1.8 out of 13 at three months, decreasing to 1.1 out of 13 at 12 months.

The patients underwent skin surgeries with an average wound size of 5.5 centimeters and up to 9 centimeters. The first group was designed to assess scar prevention in incision sites in the trunk and limbs for 12 months after the surgery. The second group is ongoing and is assessing scar formation in face and neck lesions.

The firm is recruiting for the third group of patients undergoing complex plastic and reconstructive surgeries.

Its shares jumped 6% in recent trading on Tuesday.